Dyne Therapeutics (NASDAQ:DYN) Trading Up 7% – Should You Buy?

Dyne Therapeutics, Inc. (NASDAQ:DYN) rose 7% during trading on Thursday . The company traded as high as $16.70 and last traded at $16.77. Approximately 957,536 shares were traded during trading, a decline of 64% from the average daily volume of 2,685,010 shares. The stock had previously closed at $15.68.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Robert W. Baird began coverage on shares of Dyne Therapeutics in a report on Friday, December 13th. They set an “outperform” rating and a $46.00 price target on the stock. Chardan Capital restated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Friday, January 10th. Baird R W raised Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research note on Friday, January 10th. Finally, Guggenheim restated a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $49.91.

Dyne Therapeutics Trading Up 7.7 %

The firm has a market cap of $1.72 billion, a price-to-earnings ratio of -4.74 and a beta of 1.11. The stock’s fifty day moving average price is $21.53 and its 200-day moving average price is $31.05.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). Analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Richard William Scalzo sold 1,455 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the sale, the senior vice president now owns 127,078 shares in the company, valued at $3,573,433.36. The trade was a 1.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Carlo Incerti sold 16,500 shares of Dyne Therapeutics stock in a transaction on Monday, November 18th. The shares were sold at an average price of $28.73, for a total transaction of $474,045.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 21,071 shares of company stock valued at $606,476. Company insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of DYN. FMR LLC lifted its holdings in shares of Dyne Therapeutics by 69.7% during the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company’s stock worth $324,239,000 after acquiring an additional 3,707,734 shares during the period. RTW Investments LP boosted its holdings in shares of Dyne Therapeutics by 6.8% in the 3rd quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock valued at $244,926,000 after purchasing an additional 431,503 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Dyne Therapeutics by 47.3% during the 3rd quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock worth $244,755,000 after buying an additional 2,189,339 shares during the last quarter. RA Capital Management L.P. raised its position in shares of Dyne Therapeutics by 5.5% in the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock worth $229,211,000 after buying an additional 331,940 shares during the period. Finally, State Street Corp boosted its holdings in Dyne Therapeutics by 13.8% in the third quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after acquiring an additional 440,890 shares during the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.